Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 134 The United Laboratories International Holdings Limited Annual Report 2023 39. FINANCIAL INSTRUMENTS (Continued) Financial risk management objectives and policies (Continued) Credit risk and impairment assessment (Continued) The tables below detail the credit risk exposures of the Group’s financial assets at 31 December 2023 and 2022 which are subject to ECL assessment: External Internal Gross credit credit 12m or carrying 2023 Notes rating rating lifetime ECL amount RMB’000 Pledged bank deposits 25 Aa2 to Baa3 N/A 12m ECL 972,249 Bank balances 25 Aa1 to Baa3 N/A 12m ECL 4,261,804 Other receivables and refundable deposits 24 N/A Note 1 12m ECL 97,250 Consideration receivables 24 N/A Note 4 Lifetime ECL (credit-impaired) 339,574 Banker’s acceptance bills receivables 24 A1 to Caa2 N/A 12m ECL 3,496,731 Trade receivables 24 N/A Note 2 Lifetime ECL (provision matrix) 2,378,638